nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Tamoxifen—pancreatic cancer	0.0693	0.224	CbGbCtD
Sitaxentan—CYP2C9—Tamoxifen—pancreatic cancer	0.0576	0.187	CbGbCtD
Sitaxentan—CYP2C9—Fluorouracil—pancreatic cancer	0.0425	0.137	CbGbCtD
Sitaxentan—CYP3A4—Tamoxifen—pancreatic cancer	0.0335	0.108	CbGbCtD
Sitaxentan—CYP3A4—Erlotinib—pancreatic cancer	0.0285	0.0922	CbGbCtD
Sitaxentan—CYP3A4—Irinotecan—pancreatic cancer	0.0257	0.0833	CbGbCtD
Sitaxentan—CYP3A4—Docetaxel—pancreatic cancer	0.0189	0.0611	CbGbCtD
Sitaxentan—CYP3A4—Sunitinib—pancreatic cancer	0.0188	0.0608	CbGbCtD
Sitaxentan—CYP3A4—Doxorubicin—pancreatic cancer	0.0141	0.0455	CbGbCtD
Sitaxentan—EDNRA—Signaling Pathways—ACVR1B—pancreatic cancer	0.000233	0.00107	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HEY2—pancreatic cancer	0.000232	0.00106	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GAST—pancreatic cancer	0.000226	0.00103	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000226	0.00103	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000224	0.00102	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AGTR1—pancreatic cancer	0.000223	0.00102	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—SHH—pancreatic cancer	0.000217	0.000988	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SCT—pancreatic cancer	0.000214	0.000978	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HEY1—pancreatic cancer	0.000214	0.000978	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IAPP—pancreatic cancer	0.000214	0.000976	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SSTR3—pancreatic cancer	0.000211	0.000963	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DTX1—pancreatic cancer	0.000211	0.000963	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000207	0.000946	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—SST—pancreatic cancer	0.000207	0.000943	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.000206	0.000938	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PTHLH—pancreatic cancer	0.000205	0.000937	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PTCH1—pancreatic cancer	0.000205	0.000937	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCK—pancreatic cancer	0.000205	0.000933	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000203	0.000925	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SSTR1—pancreatic cancer	0.000202	0.000924	CbGpPWpGaD
Sitaxentan—Pain—Gemcitabine—pancreatic cancer	0.0002	0.000424	CcSEcCtD
Sitaxentan—Nausea—Erlotinib—pancreatic cancer	0.0002	0.000424	CcSEcCtD
Sitaxentan—Decreased appetite—Fluorouracil—pancreatic cancer	0.0002	0.000424	CcSEcCtD
Sitaxentan—Diarrhoea—Sunitinib—pancreatic cancer	0.0002	0.000423	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GLP1R—pancreatic cancer	0.000199	0.000909	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CNR2—pancreatic cancer	0.000199	0.000909	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL8—pancreatic cancer	0.000199	0.000909	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000199	0.000421	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PPY—pancreatic cancer	0.000199	0.000906	CbGpPWpGaD
Sitaxentan—Ataxia—Doxorubicin—pancreatic cancer	0.000198	0.00042	CcSEcCtD
Sitaxentan—Feeling abnormal—Irinotecan—pancreatic cancer	0.000198	0.000419	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—pancreatic cancer	0.000198	0.000901	CbGpPWpGaD
Sitaxentan—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000198	0.000419	CcSEcCtD
Sitaxentan—Asthma—Epirubicin—pancreatic cancer	0.000197	0.000417	CcSEcCtD
Sitaxentan—Pain—Fluorouracil—pancreatic cancer	0.000197	0.000417	CcSEcCtD
Sitaxentan—Dehydration—Doxorubicin—pancreatic cancer	0.000196	0.000416	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CCKAR—pancreatic cancer	0.000196	0.000894	CbGpPWpGaD
Sitaxentan—Muscle spasms—Docetaxel—pancreatic cancer	0.000196	0.000415	CcSEcCtD
Sitaxentan—Eosinophilia—Epirubicin—pancreatic cancer	0.000195	0.000413	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SSTR2—pancreatic cancer	0.000195	0.000889	CbGpPWpGaD
Sitaxentan—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000195	0.000413	CcSEcCtD
Sitaxentan—Dry skin—Doxorubicin—pancreatic cancer	0.000193	0.00041	CcSEcCtD
Sitaxentan—Dizziness—Sunitinib—pancreatic cancer	0.000193	0.000409	CcSEcCtD
Sitaxentan—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000193	0.000409	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000193	0.000408	CcSEcCtD
Sitaxentan—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000193	0.000408	CcSEcCtD
Sitaxentan—Angina pectoris—Epirubicin—pancreatic cancer	0.000192	0.000407	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—CNR1—pancreatic cancer	0.000191	0.000871	CbGpPWpGaD
Sitaxentan—Breast disorder—Doxorubicin—pancreatic cancer	0.000191	0.000404	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—JAG2—pancreatic cancer	0.00019	0.000867	CbGpPWpGaD
Sitaxentan—Body temperature increased—Irinotecan—pancreatic cancer	0.00019	0.000402	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.00019	0.000402	CcSEcCtD
Sitaxentan—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00019	0.000402	CcSEcCtD
Sitaxentan—Bronchitis—Epirubicin—pancreatic cancer	0.000189	0.000401	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCKBR—pancreatic cancer	0.000188	0.000859	CbGpPWpGaD
Sitaxentan—Anaemia—Docetaxel—pancreatic cancer	0.000188	0.000399	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—SST—pancreatic cancer	0.000188	0.000857	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MEN1—pancreatic cancer	0.000187	0.000855	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000187	0.000854	CbGpPWpGaD
Sitaxentan—Pancytopenia—Epirubicin—pancreatic cancer	0.000187	0.000396	CcSEcCtD
Sitaxentan—Muscular weakness—Doxorubicin—pancreatic cancer	0.000186	0.000394	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000186	0.000394	CcSEcCtD
Sitaxentan—Vomiting—Sunitinib—pancreatic cancer	0.000185	0.000393	CcSEcCtD
Sitaxentan—Body temperature increased—Gemcitabine—pancreatic cancer	0.000185	0.000392	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000185	0.000843	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GCG—pancreatic cancer	0.000184	0.000841	CbGpPWpGaD
Sitaxentan—Dysuria—Epirubicin—pancreatic cancer	0.000184	0.00039	CcSEcCtD
Sitaxentan—Rash—Sunitinib—pancreatic cancer	0.000184	0.00039	CcSEcCtD
Sitaxentan—Dermatitis—Sunitinib—pancreatic cancer	0.000184	0.000389	CcSEcCtD
Sitaxentan—Urticaria—Fluorouracil—pancreatic cancer	0.000183	0.000387	CcSEcCtD
Sitaxentan—Headache—Sunitinib—pancreatic cancer	0.000183	0.000387	CcSEcCtD
Sitaxentan—Asthma—Doxorubicin—pancreatic cancer	0.000182	0.000386	CcSEcCtD
Sitaxentan—Leukopenia—Docetaxel—pancreatic cancer	0.000182	0.000386	CcSEcCtD
Sitaxentan—Pollakiuria—Epirubicin—pancreatic cancer	0.000182	0.000386	CcSEcCtD
Sitaxentan—Body temperature increased—Fluorouracil—pancreatic cancer	0.000182	0.000385	CcSEcCtD
Sitaxentan—Eosinophilia—Doxorubicin—pancreatic cancer	0.00018	0.000382	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—pancreatic cancer	0.00018	0.000822	CbGpPWpGaD
Sitaxentan—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.00018	0.000381	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000179	0.000818	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SHH—pancreatic cancer	0.000179	0.000815	CbGpPWpGaD
Sitaxentan—Weight decreased—Epirubicin—pancreatic cancer	0.000178	0.000378	CcSEcCtD
Sitaxentan—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000178	0.000376	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NOTCH4—pancreatic cancer	0.000178	0.00081	CbGpPWpGaD
Sitaxentan—Angina pectoris—Doxorubicin—pancreatic cancer	0.000178	0.000376	CcSEcCtD
Sitaxentan—Hypersensitivity—Irinotecan—pancreatic cancer	0.000177	0.000375	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—DTX4—pancreatic cancer	0.000177	0.000807	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GLI1—pancreatic cancer	0.000177	0.000807	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IAPP—pancreatic cancer	0.000177	0.000805	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000176	0.000802	CbGpPWpGaD
Sitaxentan—Infestation NOS—Epirubicin—pancreatic cancer	0.000176	0.000372	CcSEcCtD
Sitaxentan—Infestation—Epirubicin—pancreatic cancer	0.000176	0.000372	CcSEcCtD
Sitaxentan—Bronchitis—Doxorubicin—pancreatic cancer	0.000175	0.000371	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000175	0.000796	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CNR1—pancreatic cancer	0.000173	0.000791	CbGpPWpGaD
Sitaxentan—Chest pain—Docetaxel—pancreatic cancer	0.000173	0.000367	CcSEcCtD
Sitaxentan—Nausea—Sunitinib—pancreatic cancer	0.000173	0.000367	CcSEcCtD
Sitaxentan—Pancytopenia—Doxorubicin—pancreatic cancer	0.000173	0.000367	CcSEcCtD
Sitaxentan—Renal failure—Epirubicin—pancreatic cancer	0.000173	0.000366	CcSEcCtD
Sitaxentan—Asthenia—Irinotecan—pancreatic cancer	0.000172	0.000365	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000172	0.000785	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NRP1—pancreatic cancer	0.000172	0.000785	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000172	0.000365	CcSEcCtD
Sitaxentan—Jaundice—Epirubicin—pancreatic cancer	0.000171	0.000363	CcSEcCtD
Sitaxentan—Stomatitis—Epirubicin—pancreatic cancer	0.000171	0.000363	CcSEcCtD
Sitaxentan—Conjunctivitis—Epirubicin—pancreatic cancer	0.000171	0.000362	CcSEcCtD
Sitaxentan—Dysuria—Doxorubicin—pancreatic cancer	0.00017	0.000361	CcSEcCtD
Sitaxentan—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00017	0.000359	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PTCH1—pancreatic cancer	0.000169	0.000773	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTHLH—pancreatic cancer	0.000169	0.000773	CbGpPWpGaD
Sitaxentan—Dry mouth—Docetaxel—pancreatic cancer	0.000169	0.000359	CcSEcCtD
Sitaxentan—Pollakiuria—Doxorubicin—pancreatic cancer	0.000168	0.000357	CcSEcCtD
Sitaxentan—Asthenia—Gemcitabine—pancreatic cancer	0.000168	0.000356	CcSEcCtD
Sitaxentan—Haematuria—Epirubicin—pancreatic cancer	0.000167	0.000355	CcSEcCtD
Sitaxentan—Confusional state—Docetaxel—pancreatic cancer	0.000167	0.000355	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—GCG—pancreatic cancer	0.000167	0.000763	CbGpPWpGaD
Sitaxentan—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000166	0.000352	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000166	0.000352	CcSEcCtD
Sitaxentan—Oedema—Docetaxel—pancreatic cancer	0.000166	0.000352	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—HEY2—pancreatic cancer	0.000166	0.000756	CbGpPWpGaD
Sitaxentan—Epistaxis—Epirubicin—pancreatic cancer	0.000166	0.000351	CcSEcCtD
Sitaxentan—Infection—Docetaxel—pancreatic cancer	0.000165	0.00035	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—pancreatic cancer	0.000165	0.000349	CcSEcCtD
Sitaxentan—Sinusitis—Epirubicin—pancreatic cancer	0.000165	0.000349	CcSEcCtD
Sitaxentan—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000164	0.000348	CcSEcCtD
Sitaxentan—Diarrhoea—Irinotecan—pancreatic cancer	0.000164	0.000348	CcSEcCtD
Sitaxentan—Nervous system disorder—Docetaxel—pancreatic cancer	0.000163	0.000345	CcSEcCtD
Sitaxentan—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000163	0.000345	CcSEcCtD
Sitaxentan—Infestation NOS—Doxorubicin—pancreatic cancer	0.000163	0.000344	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—pancreatic cancer	0.000163	0.000344	CcSEcCtD
Sitaxentan—Tachycardia—Docetaxel—pancreatic cancer	0.000162	0.000343	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—GAST—pancreatic cancer	0.000162	0.000738	CbGpPWpGaD
Sitaxentan—Skin disorder—Docetaxel—pancreatic cancer	0.000161	0.000342	CcSEcCtD
Sitaxentan—Bradycardia—Epirubicin—pancreatic cancer	0.000161	0.00034	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.00016	0.000732	CbGpPWpGaD
Sitaxentan—Diarrhoea—Gemcitabine—pancreatic cancer	0.00016	0.000339	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—pancreatic cancer	0.00016	0.000338	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—AGTR1—pancreatic cancer	0.00016	0.000728	CbGpPWpGaD
Sitaxentan—Dizziness—Irinotecan—pancreatic cancer	0.000159	0.000337	CcSEcCtD
Sitaxentan—Haemoglobin—Epirubicin—pancreatic cancer	0.000158	0.000336	CcSEcCtD
Sitaxentan—Stomatitis—Doxorubicin—pancreatic cancer	0.000158	0.000336	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—pancreatic cancer	0.000158	0.000336	CcSEcCtD
Sitaxentan—Anorexia—Docetaxel—pancreatic cancer	0.000158	0.000335	CcSEcCtD
Sitaxentan—Rhinitis—Epirubicin—pancreatic cancer	0.000158	0.000335	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000158	0.000335	CcSEcCtD
Sitaxentan—Haemorrhage—Epirubicin—pancreatic cancer	0.000158	0.000334	CcSEcCtD
Sitaxentan—Hepatitis—Epirubicin—pancreatic cancer	0.000158	0.000334	CcSEcCtD
Sitaxentan—Diarrhoea—Fluorouracil—pancreatic cancer	0.000157	0.000334	CcSEcCtD
Sitaxentan—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000156	0.00033	CcSEcCtD
Sitaxentan—Oedema peripheral—Epirubicin—pancreatic cancer	0.000155	0.000329	CcSEcCtD
Sitaxentan—Hypotension—Docetaxel—pancreatic cancer	0.000155	0.000329	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SST—pancreatic cancer	0.000155	0.000707	CbGpPWpGaD
Sitaxentan—Haematuria—Doxorubicin—pancreatic cancer	0.000155	0.000328	CcSEcCtD
Sitaxentan—Urethral disorder—Epirubicin—pancreatic cancer	0.000155	0.000327	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000154	0.000326	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SCT—pancreatic cancer	0.000153	0.0007	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HEY1—pancreatic cancer	0.000153	0.0007	CbGpPWpGaD
Sitaxentan—Epistaxis—Doxorubicin—pancreatic cancer	0.000153	0.000325	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000153	0.000697	CbGpPWpGaD
Sitaxentan—Vomiting—Irinotecan—pancreatic cancer	0.000153	0.000324	CcSEcCtD
Sitaxentan—Sinusitis—Doxorubicin—pancreatic cancer	0.000152	0.000323	CcSEcCtD
Sitaxentan—Dizziness—Fluorouracil—pancreatic cancer	0.000152	0.000322	CcSEcCtD
Sitaxentan—Visual impairment—Epirubicin—pancreatic cancer	0.000152	0.000322	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—JAG1—pancreatic cancer	0.000152	0.000692	CbGpPWpGaD
Sitaxentan—Rash—Irinotecan—pancreatic cancer	0.000151	0.000321	CcSEcCtD
Sitaxentan—Dermatitis—Irinotecan—pancreatic cancer	0.000151	0.000321	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NOTCH3—pancreatic cancer	0.000151	0.000689	CbGpPWpGaD
Sitaxentan—Headache—Irinotecan—pancreatic cancer	0.00015	0.000319	CcSEcCtD
Sitaxentan—Insomnia—Docetaxel—pancreatic cancer	0.00015	0.000318	CcSEcCtD
Sitaxentan—Vomiting—Gemcitabine—pancreatic cancer	0.000149	0.000315	CcSEcCtD
Sitaxentan—Bradycardia—Doxorubicin—pancreatic cancer	0.000149	0.000315	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000148	0.000677	CbGpPWpGaD
Sitaxentan—Somnolence—Docetaxel—pancreatic cancer	0.000148	0.000313	CcSEcCtD
Sitaxentan—Rash—Gemcitabine—pancreatic cancer	0.000148	0.000313	CcSEcCtD
Sitaxentan—Dermatitis—Gemcitabine—pancreatic cancer	0.000147	0.000312	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—pancreatic cancer	0.000147	0.000312	CcSEcCtD
Sitaxentan—Tinnitus—Epirubicin—pancreatic cancer	0.000147	0.000311	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—pancreatic cancer	0.000147	0.000311	CcSEcCtD
Sitaxentan—Headache—Gemcitabine—pancreatic cancer	0.000147	0.000311	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCK—pancreatic cancer	0.000146	0.000668	CbGpPWpGaD
Sitaxentan—Cardiac disorder—Epirubicin—pancreatic cancer	0.000146	0.00031	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—pancreatic cancer	0.000146	0.00031	CcSEcCtD
Sitaxentan—Vomiting—Fluorouracil—pancreatic cancer	0.000146	0.00031	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—pancreatic cancer	0.000146	0.00031	CcSEcCtD
Sitaxentan—Dyspepsia—Docetaxel—pancreatic cancer	0.000146	0.00031	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—pancreatic cancer	0.000146	0.000309	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—pancreatic cancer	0.000146	0.000309	CcSEcCtD
Sitaxentan—Rash—Fluorouracil—pancreatic cancer	0.000145	0.000307	CcSEcCtD
Sitaxentan—Dermatitis—Fluorouracil—pancreatic cancer	0.000145	0.000307	CcSEcCtD
Sitaxentan—Decreased appetite—Docetaxel—pancreatic cancer	0.000144	0.000306	CcSEcCtD
Sitaxentan—Headache—Fluorouracil—pancreatic cancer	0.000144	0.000305	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000144	0.000305	CcSEcCtD
Sitaxentan—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000144	0.000305	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000143	0.000304	CcSEcCtD
Sitaxentan—Fatigue—Docetaxel—pancreatic cancer	0.000143	0.000303	CcSEcCtD
Sitaxentan—Angiopathy—Epirubicin—pancreatic cancer	0.000143	0.000303	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—CNR1—pancreatic cancer	0.000143	0.000652	CbGpPWpGaD
Sitaxentan—Urethral disorder—Doxorubicin—pancreatic cancer	0.000143	0.000303	CcSEcCtD
Sitaxentan—Nausea—Irinotecan—pancreatic cancer	0.000143	0.000302	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CNR2—pancreatic cancer	0.000143	0.000651	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GLP1R—pancreatic cancer	0.000143	0.000651	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL8—pancreatic cancer	0.000143	0.00065	CbGpPWpGaD
Sitaxentan—Immune system disorder—Epirubicin—pancreatic cancer	0.000142	0.000302	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000142	0.000301	CcSEcCtD
Sitaxentan—Constipation—Docetaxel—pancreatic cancer	0.000142	0.000301	CcSEcCtD
Sitaxentan—Pain—Docetaxel—pancreatic cancer	0.000142	0.000301	CcSEcCtD
Sitaxentan—Visual impairment—Doxorubicin—pancreatic cancer	0.000141	0.000298	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CCKAR—pancreatic cancer	0.00014	0.00064	CbGpPWpGaD
Sitaxentan—Alopecia—Epirubicin—pancreatic cancer	0.000139	0.000295	CcSEcCtD
Sitaxentan—Nausea—Gemcitabine—pancreatic cancer	0.000139	0.000295	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000139	0.000633	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GCG—pancreatic cancer	0.000138	0.00063	CbGpPWpGaD
Sitaxentan—Mental disorder—Epirubicin—pancreatic cancer	0.000138	0.000293	CcSEcCtD
Sitaxentan—Malnutrition—Epirubicin—pancreatic cancer	0.000137	0.000291	CcSEcCtD
Sitaxentan—Feeling abnormal—Docetaxel—pancreatic cancer	0.000137	0.00029	CcSEcCtD
Sitaxentan—Nausea—Fluorouracil—pancreatic cancer	0.000137	0.00029	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—pancreatic cancer	0.000136	0.000289	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—JAG2—pancreatic cancer	0.000136	0.000621	CbGpPWpGaD
Sitaxentan—Tinnitus—Doxorubicin—pancreatic cancer	0.000136	0.000288	CcSEcCtD
Sitaxentan—Flushing—Doxorubicin—pancreatic cancer	0.000135	0.000287	CcSEcCtD
Sitaxentan—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000135	0.000287	CcSEcCtD
Sitaxentan—Tension—Epirubicin—pancreatic cancer	0.000135	0.000285	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000134	0.000613	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MEN1—pancreatic cancer	0.000134	0.000612	CbGpPWpGaD
Sitaxentan—Nervousness—Epirubicin—pancreatic cancer	0.000133	0.000282	CcSEcCtD
Sitaxentan—Angiopathy—Doxorubicin—pancreatic cancer	0.000132	0.00028	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—pancreatic cancer	0.000132	0.00028	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—AGTR1—pancreatic cancer	0.000132	0.000601	CbGpPWpGaD
Sitaxentan—Immune system disorder—Doxorubicin—pancreatic cancer	0.000132	0.000279	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000131	0.000279	CcSEcCtD
Sitaxentan—Body temperature increased—Docetaxel—pancreatic cancer	0.000131	0.000278	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—STK11—pancreatic cancer	0.00013	0.000592	CbGpPWpGaD
Sitaxentan—Alopecia—Doxorubicin—pancreatic cancer	0.000129	0.000273	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SHH—pancreatic cancer	0.000128	0.000584	CbGpPWpGaD
Sitaxentan—Mental disorder—Doxorubicin—pancreatic cancer	0.000128	0.000271	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000127	0.00027	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH4—pancreatic cancer	0.000127	0.00058	CbGpPWpGaD
Sitaxentan—Malnutrition—Doxorubicin—pancreatic cancer	0.000127	0.000269	CcSEcCtD
Sitaxentan—Anaemia—Epirubicin—pancreatic cancer	0.000127	0.000269	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—IAPP—pancreatic cancer	0.000126	0.000576	CbGpPWpGaD
Sitaxentan—Agitation—Epirubicin—pancreatic cancer	0.000126	0.000267	CcSEcCtD
Sitaxentan—Tension—Doxorubicin—pancreatic cancer	0.000125	0.000264	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—pancreatic cancer	0.000124	0.000262	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—pancreatic cancer	0.000123	0.000261	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—pancreatic cancer	0.000123	0.000261	CcSEcCtD
Sitaxentan—Leukopenia—Epirubicin—pancreatic cancer	0.000123	0.00026	CcSEcCtD
Sitaxentan—Hypersensitivity—Docetaxel—pancreatic cancer	0.000122	0.000259	CcSEcCtD
Sitaxentan—Muscle spasms—Doxorubicin—pancreatic cancer	0.000122	0.000259	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000122	0.000557	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTHLH—pancreatic cancer	0.000121	0.000553	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTCH1—pancreatic cancer	0.000121	0.000553	CbGpPWpGaD
Sitaxentan—Asthenia—Docetaxel—pancreatic cancer	0.000119	0.000252	CcSEcCtD
Sitaxentan—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000118	0.00025	CcSEcCtD
Sitaxentan—Anaemia—Doxorubicin—pancreatic cancer	0.000117	0.000249	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000117	0.000534	CbGpPWpGaD
Sitaxentan—Chest pain—Epirubicin—pancreatic cancer	0.000117	0.000248	CcSEcCtD
Sitaxentan—Agitation—Doxorubicin—pancreatic cancer	0.000117	0.000247	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000116	0.000246	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—pancreatic cancer	0.000115	0.000245	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—pancreatic cancer	0.000115	0.000243	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—pancreatic cancer	0.000114	0.000242	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—pancreatic cancer	0.000114	0.000242	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—SMAD4—pancreatic cancer	0.000114	0.000519	CbGpPWpGaD
Sitaxentan—Leukopenia—Doxorubicin—pancreatic cancer	0.000114	0.000241	CcSEcCtD
Sitaxentan—Diarrhoea—Docetaxel—pancreatic cancer	0.000114	0.000241	CcSEcCtD
Sitaxentan—Confusional state—Epirubicin—pancreatic cancer	0.000113	0.000239	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000113	0.000513	CbGpPWpGaD
Sitaxentan—Oedema—Epirubicin—pancreatic cancer	0.000112	0.000237	CcSEcCtD
Sitaxentan—Infection—Epirubicin—pancreatic cancer	0.000111	0.000236	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HES1—pancreatic cancer	0.000111	0.000507	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SST—pancreatic cancer	0.000111	0.000506	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Epirubicin—pancreatic cancer	0.00011	0.000233	CcSEcCtD
Sitaxentan—Dizziness—Docetaxel—pancreatic cancer	0.00011	0.000233	CcSEcCtD
Sitaxentan—Thrombocytopenia—Epirubicin—pancreatic cancer	0.00011	0.000232	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000109	0.000499	CbGpPWpGaD
Sitaxentan—Tachycardia—Epirubicin—pancreatic cancer	0.000109	0.000232	CcSEcCtD
Sitaxentan—Skin disorder—Epirubicin—pancreatic cancer	0.000109	0.000231	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—JAG1—pancreatic cancer	0.000109	0.000495	CbGpPWpGaD
Sitaxentan—Chest pain—Doxorubicin—pancreatic cancer	0.000108	0.000229	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH3—pancreatic cancer	0.000108	0.000493	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000107	0.000228	CcSEcCtD
Sitaxentan—Discomfort—Doxorubicin—pancreatic cancer	0.000107	0.000226	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—pancreatic cancer	0.000107	0.000226	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000106	0.000485	CbGpPWpGaD
Sitaxentan—Dry mouth—Doxorubicin—pancreatic cancer	0.000106	0.000224	CcSEcCtD
Sitaxentan—Vomiting—Docetaxel—pancreatic cancer	0.000106	0.000224	CcSEcCtD
Sitaxentan—Rash—Docetaxel—pancreatic cancer	0.000105	0.000222	CcSEcCtD
Sitaxentan—Hypotension—Epirubicin—pancreatic cancer	0.000105	0.000222	CcSEcCtD
Sitaxentan—Dermatitis—Docetaxel—pancreatic cancer	0.000105	0.000222	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—pancreatic cancer	0.000105	0.000221	CcSEcCtD
Sitaxentan—Headache—Docetaxel—pancreatic cancer	0.000104	0.00022	CcSEcCtD
Sitaxentan—Oedema—Doxorubicin—pancreatic cancer	0.000104	0.00022	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—pancreatic cancer	0.000103	0.000218	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—CNR1—pancreatic cancer	0.000102	0.000467	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL8—pancreatic cancer	0.000102	0.000466	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000102	0.000215	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000101	0.000215	CcSEcCtD
Sitaxentan—Insomnia—Epirubicin—pancreatic cancer	0.000101	0.000215	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—pancreatic cancer	0.000101	0.000214	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—pancreatic cancer	0.000101	0.000213	CcSEcCtD
Sitaxentan—Somnolence—Epirubicin—pancreatic cancer	9.96e-05	0.000211	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CG—pancreatic cancer	9.94e-05	0.000453	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GCG—pancreatic cancer	9.89e-05	0.000451	CbGpPWpGaD
Sitaxentan—Anorexia—Doxorubicin—pancreatic cancer	9.88e-05	0.000209	CcSEcCtD
Sitaxentan—Nausea—Docetaxel—pancreatic cancer	9.86e-05	0.000209	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—pancreatic cancer	9.86e-05	0.000209	CcSEcCtD
Sitaxentan—Decreased appetite—Epirubicin—pancreatic cancer	9.74e-05	0.000206	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—TERT—pancreatic cancer	9.73e-05	0.000444	CbGpPWpGaD
Sitaxentan—Hypotension—Doxorubicin—pancreatic cancer	9.68e-05	0.000205	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.67e-05	0.000205	CcSEcCtD
Sitaxentan—Fatigue—Epirubicin—pancreatic cancer	9.66e-05	0.000205	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CD—pancreatic cancer	9.62e-05	0.000439	CbGpPWpGaD
Sitaxentan—Constipation—Epirubicin—pancreatic cancer	9.58e-05	0.000203	CcSEcCtD
Sitaxentan—Pain—Epirubicin—pancreatic cancer	9.58e-05	0.000203	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—AGTR1—pancreatic cancer	9.43e-05	0.00043	CbGpPWpGaD
Sitaxentan—Insomnia—Doxorubicin—pancreatic cancer	9.37e-05	0.000199	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HIF1A—pancreatic cancer	9.31e-05	0.000425	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STK11—pancreatic cancer	9.3e-05	0.000424	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TSC2—pancreatic cancer	9.29e-05	0.000424	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Epirubicin—pancreatic cancer	9.23e-05	0.000196	CcSEcCtD
Sitaxentan—Somnolence—Doxorubicin—pancreatic cancer	9.21e-05	0.000195	CcSEcCtD
Sitaxentan—Dyspepsia—Doxorubicin—pancreatic cancer	9.12e-05	0.000193	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—APOE—pancreatic cancer	9.09e-05	0.000414	CbGpPWpGaD
Sitaxentan—Decreased appetite—Doxorubicin—pancreatic cancer	9.01e-05	0.000191	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	8.95e-05	0.00019	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—pancreatic cancer	8.94e-05	0.000189	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—KDR—pancreatic cancer	8.9e-05	0.000406	CbGpPWpGaD
Sitaxentan—Urticaria—Epirubicin—pancreatic cancer	8.9e-05	0.000189	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—pancreatic cancer	8.86e-05	0.000188	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—pancreatic cancer	8.86e-05	0.000188	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—pancreatic cancer	8.85e-05	0.000188	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CD—pancreatic cancer	8.73e-05	0.000398	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Doxorubicin—pancreatic cancer	8.54e-05	0.000181	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—NFKBIA—pancreatic cancer	8.47e-05	0.000386	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOTCH1—pancreatic cancer	8.39e-05	0.000383	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CB—pancreatic cancer	8.38e-05	0.000382	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Epirubicin—pancreatic cancer	8.25e-05	0.000175	CcSEcCtD
Sitaxentan—Urticaria—Doxorubicin—pancreatic cancer	8.23e-05	0.000174	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CG—pancreatic cancer	8.2e-05	0.000374	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—NRAS—pancreatic cancer	8.2e-05	0.000374	CbGpPWpGaD
Sitaxentan—Body temperature increased—Doxorubicin—pancreatic cancer	8.19e-05	0.000174	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—SMAD4—pancreatic cancer	8.14e-05	0.000371	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGF—pancreatic cancer	8.11e-05	0.00037	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL8—pancreatic cancer	8.06e-05	0.000367	CbGpPWpGaD
Sitaxentan—Asthenia—Epirubicin—pancreatic cancer	8.04e-05	0.00017	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—HES1—pancreatic cancer	7.95e-05	0.000363	CbGpPWpGaD
Sitaxentan—Diarrhoea—Epirubicin—pancreatic cancer	7.66e-05	0.000162	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—pancreatic cancer	7.64e-05	0.000162	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CB—pancreatic cancer	7.61e-05	0.000347	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—pancreatic cancer	7.47e-05	0.000341	CbGpPWpGaD
Sitaxentan—Asthenia—Doxorubicin—pancreatic cancer	7.44e-05	0.000158	CcSEcCtD
Sitaxentan—Dizziness—Epirubicin—pancreatic cancer	7.41e-05	0.000157	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL8—pancreatic cancer	7.32e-05	0.000334	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CD—pancreatic cancer	7.21e-05	0.000329	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.14e-05	0.000326	CbGpPWpGaD
Sitaxentan—Vomiting—Epirubicin—pancreatic cancer	7.12e-05	0.000151	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—pancreatic cancer	7.09e-05	0.00015	CcSEcCtD
Sitaxentan—Rash—Epirubicin—pancreatic cancer	7.06e-05	0.00015	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—KRAS—pancreatic cancer	7.06e-05	0.000322	CbGpPWpGaD
Sitaxentan—Dermatitis—Epirubicin—pancreatic cancer	7.06e-05	0.00015	CcSEcCtD
Sitaxentan—Headache—Epirubicin—pancreatic cancer	7.02e-05	0.000149	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TERT—pancreatic cancer	6.97e-05	0.000318	CbGpPWpGaD
Sitaxentan—Dizziness—Doxorubicin—pancreatic cancer	6.85e-05	0.000145	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—HIF1A—pancreatic cancer	6.66e-05	0.000304	CbGpPWpGaD
Sitaxentan—Nausea—Epirubicin—pancreatic cancer	6.65e-05	0.000141	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—TSC2—pancreatic cancer	6.65e-05	0.000303	CbGpPWpGaD
Sitaxentan—Vomiting—Doxorubicin—pancreatic cancer	6.59e-05	0.00014	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism—PRSS1—pancreatic cancer	6.59e-05	0.000301	CbGpPWpGaD
Sitaxentan—Rash—Doxorubicin—pancreatic cancer	6.53e-05	0.000138	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—pancreatic cancer	6.53e-05	0.000138	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—APOE—pancreatic cancer	6.5e-05	0.000297	CbGpPWpGaD
Sitaxentan—Headache—Doxorubicin—pancreatic cancer	6.49e-05	0.000138	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CA—pancreatic cancer	6.48e-05	0.000296	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KDR—pancreatic cancer	6.37e-05	0.000291	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CB—pancreatic cancer	6.28e-05	0.000287	CbGpPWpGaD
Sitaxentan—Nausea—Doxorubicin—pancreatic cancer	6.16e-05	0.00013	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—NFKBIA—pancreatic cancer	6.06e-05	0.000276	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL8—pancreatic cancer	6.04e-05	0.000275	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PRSS1—pancreatic cancer	6.01e-05	0.000274	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH1—pancreatic cancer	6e-05	0.000274	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—pancreatic cancer	6e-05	0.000274	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CG—pancreatic cancer	5.87e-05	0.000268	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—NRAS—pancreatic cancer	5.87e-05	0.000268	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AKT1—pancreatic cancer	5.83e-05	0.000266	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGF—pancreatic cancer	5.8e-05	0.000265	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CASP3—pancreatic cancer	5.78e-05	0.000264	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ARG2—pancreatic cancer	5.71e-05	0.000261	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—pancreatic cancer	5.63e-05	0.000257	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CTNNB1—pancreatic cancer	5.57e-05	0.000254	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—pancreatic cancer	5.46e-05	0.000249	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTEN—pancreatic cancer	5.43e-05	0.000248	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—pancreatic cancer	5.35e-05	0.000244	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AKT1—pancreatic cancer	5.3e-05	0.000242	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ARG2—pancreatic cancer	5.21e-05	0.000238	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CD—pancreatic cancer	5.16e-05	0.000235	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.11e-05	0.000233	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—pancreatic cancer	5.05e-05	0.00023	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SRC—pancreatic cancer	5.04e-05	0.00023	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TYMP—pancreatic cancer	4.99e-05	0.000228	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VEGFA—pancreatic cancer	4.9e-05	0.000224	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—STAT3—pancreatic cancer	4.86e-05	0.000222	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NRAS—pancreatic cancer	4.84e-05	0.000221	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—pancreatic cancer	4.64e-05	0.000212	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TYMP—pancreatic cancer	4.55e-05	0.000208	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—pancreatic cancer	4.51e-05	0.000206	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFB1—pancreatic cancer	4.5e-05	0.000205	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CB—pancreatic cancer	4.5e-05	0.000205	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—pancreatic cancer	4.41e-05	0.000201	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—pancreatic cancer	4.32e-05	0.000197	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—pancreatic cancer	4.29e-05	0.000196	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AKT1—pancreatic cancer	4.17e-05	0.00019	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—pancreatic cancer	4.17e-05	0.00019	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CASP3—pancreatic cancer	4.14e-05	0.000189	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	4.12e-05	0.000188	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—pancreatic cancer	4.03e-05	0.000184	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GLP1R—pancreatic cancer	4.03e-05	0.000184	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CTNNB1—pancreatic cancer	3.99e-05	0.000182	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PRSS1—pancreatic cancer	3.96e-05	0.000181	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—DPYD—pancreatic cancer	3.96e-05	0.000181	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—pancreatic cancer	3.91e-05	0.000178	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—pancreatic cancer	3.89e-05	0.000177	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—pancreatic cancer	3.83e-05	0.000175	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AKT1—pancreatic cancer	3.79e-05	0.000173	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	3.76e-05	0.000171	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.76e-05	0.000171	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.72e-05	0.00017	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—pancreatic cancer	3.71e-05	0.000169	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GLP1R—pancreatic cancer	3.67e-05	0.000167	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—DPYD—pancreatic cancer	3.61e-05	0.000165	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SRC—pancreatic cancer	3.6e-05	0.000164	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.59e-05	0.000164	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—pancreatic cancer	3.54e-05	0.000162	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VEGFA—pancreatic cancer	3.51e-05	0.00016	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—STAT3—pancreatic cancer	3.48e-05	0.000159	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NRAS—pancreatic cancer	3.47e-05	0.000158	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ARG2—pancreatic cancer	3.44e-05	0.000157	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	3.43e-05	0.000156	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.39e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.27e-05	0.000149	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.27e-05	0.000149	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—pancreatic cancer	3.23e-05	0.000147	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFB1—pancreatic cancer	3.22e-05	0.000147	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—pancreatic cancer	3.16e-05	0.000144	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKT1—pancreatic cancer	3.13e-05	0.000143	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TYMP—pancreatic cancer	3e-05	0.000137	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—pancreatic cancer	2.98e-05	0.000136	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.98e-05	0.000136	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CD44—pancreatic cancer	2.91e-05	0.000133	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.85e-05	0.00013	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.82e-05	0.000129	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GCG—pancreatic cancer	2.79e-05	0.000127	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—pancreatic cancer	2.74e-05	0.000125	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CD44—pancreatic cancer	2.65e-05	0.000121	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—pancreatic cancer	2.65e-05	0.000121	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—STK11—pancreatic cancer	2.62e-05	0.00012	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.6e-05	0.000119	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.57e-05	0.000117	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GCG—pancreatic cancer	2.54e-05	0.000116	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—pancreatic cancer	2.54e-05	0.000116	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.46e-05	0.000112	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GLP1R—pancreatic cancer	2.42e-05	0.00011	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—STK11—pancreatic cancer	2.39e-05	0.000109	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.38e-05	0.000109	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.26e-05	0.000103	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TYMS—pancreatic cancer	2.26e-05	0.000103	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.25e-05	0.000102	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKT1—pancreatic cancer	2.24e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TYMS—pancreatic cancer	2.06e-05	9.39e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—APOE—pancreatic cancer	1.84e-05	8.37e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CD44—pancreatic cancer	1.75e-05	7.98e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.74e-05	7.92e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GCG—pancreatic cancer	1.68e-05	7.65e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—APOE—pancreatic cancer	1.67e-05	7.63e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	1.66e-05	7.55e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARG—pancreatic cancer	1.6e-05	7.29e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.58e-05	7.22e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—STK11—pancreatic cancer	1.58e-05	7.2e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	1.51e-05	6.89e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARG—pancreatic cancer	1.46e-05	6.65e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	1.46e-05	6.64e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.36e-05	6.19e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	1.33e-05	6.06e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.27e-05	5.79e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.26e-05	5.74e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.16e-05	5.28e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.15e-05	5.23e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—APOE—pancreatic cancer	1.1e-05	5.03e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—pancreatic cancer	1.1e-05	5e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—pancreatic cancer	1e-05	4.56e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	9.96e-06	4.54e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARG—pancreatic cancer	9.61e-06	4.38e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	8.75e-06	3.99e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	7.74e-06	3.53e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	7.63e-06	3.48e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—pancreatic cancer	7.56e-06	3.45e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	7.05e-06	3.22e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—pancreatic cancer	6.59e-06	3.01e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AKT1—pancreatic cancer	6.32e-06	2.88e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AKT1—pancreatic cancer	5.76e-06	2.63e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.65e-06	2.12e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.8e-06	1.73e-05	CbGpPWpGaD
